Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fractionEsther González-López, Pablo García‐Pavía, María Gallego‐Delgado et al.|European Heart Journal|2015Cited by 1.1k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial DiseasesPablo García‐Pavía, Aleš Linhart, Claudio Rapezzi et al.|European Heart Journal|2021Cited by 1.1k
A new staging system for cardiac transthyretin amyloidosisJulian D. Gillmore, Philip N. Hawkins, Thibaud Damy et al.|European Heart Journal|2017Cited by 740
Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving mythsEsther González-López, Pablo García‐Pavía, Christian Gagliardi et al.|European Heart Journal|2017Cited by 373
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp> orking <scp>G</scp> roup on <scp>M</scp> yocardial and <scp>P</scp> ericardial <scp>D</scp> iseasesPablo García‐Pavía, Aleš Linhart, Claudio Rapezzi et al.|European Journal of Heart Failure|2021Cited by 330